EGFR and familial pancreatic carcinoma: Furthermore, drug combinations may affect previously unknown molecular targets, including targets which have been reported to be implicated in human pancreatic cancers, such as epidermal growth factor receptor (EGFR), phosphoinositide 3-kinases/protein kinase alpha/mammalian target of rapamycin (PI3K/Akt/mTOR), cholecystokinin receptors (CCKR), WNT/β-catenin, NOTCH and special AT-rich sequence-binding protein 2 (SATB2) [43,49,50,51,52,53,54], or even novel targets.